Only one study [36], based on a subset of 761 of 1,867 trial patients, provided direct evidence on ERCC1 as a predictive biomarker in the form of an interaction between randomised treatment and ERCC1 status which was statistically significant (p = 0.009), with adjuvant cisplatin-based chemotherapy prolonging survival compared with observation in patients with ERCC1-negative tumours (adjusted HR = 0.65; 95%CI: 0.50–0.86) but not in patients with ERCC1-positive tumours (adjusted HR = 1.14; 95%CI: 0.84–1.55). Here, ERCC1 is linked to neoplasm.